1. WHO. Global Tuberculosis Report 2017. Geneva, Switzerland: World Health Organization; 2016. [consultado 15 Dic 2017]. Disponible en: http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf
2. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults;Steingart;Cochrane Database of Syst Rev,2014
3. WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System Policy Statement. Geneva: World Health Organization; 2011. [consultado 15 Dic 2017]. Disponible en: http://apps.who.int/iris/bitstream/10665/44586/1/9789241501545_eng.pdf
4. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: World Health Organization; 2017. [consultado 15 Dic 2017]. Disponible en: http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1
5. Guía de terapéutica antimicrobiana EDN 26.a ed;Mensa,2016